Af­ter M&A fell through, Ther­a­peu­tic­sMD sells hor­mone ther­a­py, con­tra­cep­tive ring for $140M cash plus roy­al­ties

Ther­a­peu­tic­sMD, a women’s health com­pa­ny whose one-time bil­lion-dol­lar val­u­a­tion seems a dis­tant mem­o­ry as its block­buster as­pi­ra­tions pe­tered out, is fi­nal­ly cash­ing out.

Aus­tralia’s Mayne Phar­ma is pay­ing $140 mil­lion up­front to li­cense es­sen­tial­ly Ther­a­peu­tic­sMD’s whole port­fo­lio, in­clud­ing two pre­scrip­tion drugs that treat con­di­tions re­lat­ing to menopause, a con­tra­cep­tive vagi­nal ring as well as its pre­scrip­tion pre­na­tal vi­t­a­min brands.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER